scholarly journals Progress in Understanding and Treating Parkinson's Disease

Author(s):  
André Barbeau

SUMMARY:This review evaluates the long-term results of Levodopa therapy in Parkinson's disease upon quality of life, prolongation of survival and excess mortality. It also focuses on recent and new therapeutic approaches: Levodopa in comhindation with a Dopa-decarboxylase inhibitor or MAO-B inhibitor, dopamine agonists and an active tripeptide: L-prolyl-L-leucylglycine amide (M1F-I). It ends by looking at new avenues of etiological research in Parkinson's disease which may indicate specific accelerated ageing of catecholaminergic (pigmented) neuronal systems.

2021 ◽  
Vol 11 (4) ◽  
pp. 416
Author(s):  
Carla Piano ◽  
Francesco Bove ◽  
Delia Mulas ◽  
Enrico Di Stasio ◽  
Alfonso Fasano ◽  
...  

Previous investigations have reported on the motor benefits and safety of chronic extradural motor cortex stimulation (EMCS) for patients with Parkinson’s disease (PD), but studies addressing the long-term clinical outcome are still lacking. In this study, nine consecutive PD patients who underwent EMCS were prospectively recruited, with a mean follow-up time of 5.1 ± 2.5 years. As compared to the preoperatory baseline, the Unified Parkinson’s Disease Rating Scale (UPDRS)-III in the off-medication condition significantly decreased by 13.8% at 12 months, 16.1% at 18 months, 18.4% at 24 months, 21% at 36 months, 15.6% at 60 months, and 8.6% at 72 months. The UPDRS-IV decreased by 30.8% at 12 months, 22.1% at 24 months, 25% at 60 months, and 36.5% at 72 months. Dopaminergic therapy showed a progressive reduction, significant at 60 months (11.8%). Quality of life improved by 18.0% at 12 months, and 22.4% at 60 months. No surgical complication, cognitive or behavioral change occurred. The only adverse event reported was an infection of the implantable pulse generator pocket. Even in the long-term follow-up, EMCS was shown to be a safe and effective treatment option in PD patients, resulting in improvements in motor symptoms and quality of life, and reductions in motor complications and dopaminergic therapy.


Synapse ◽  
2018 ◽  
Vol 73 (3) ◽  
pp. e22077 ◽  
Author(s):  
Steven Vetel ◽  
Sophie Sérrière ◽  
Johnny Vercouillie ◽  
Jackie Vergote ◽  
Gabrielle Chicheri ◽  
...  

Author(s):  
J. Eric Ahlskog

Carbidopa/levodopa is well recognized to effectively treat movement (“motor”) problems in DLB and PDD, as well as in typical Parkinson’s disease. However, symptoms responding to levodopa also include anxiety and insomnia. Moreover, pain control may improve with optimized levodopa dosages. The role for carbidopa/levodopa in treating these symptoms cannot be overemphasized; quality of life may markedly improve with optimized dosage. Anxiety is a normal part of the human existence. It is normal to become nervous before a school test or speaking before a large audience. In fact, some of us are especially nervous or anxious as part of our normal makeup. However, newly developing anxiety is a frequent component of DLB, PDD, and Parkinson’s disease. In the context of these disorders, anxiety may occasionally be the most troublesome symptom, even bordering on panic. The good news is that this is often treatable with carbidopa/ levodopa. The usual anxiety everyone experiences, or the excessive anxiety of nervous people, does not respond to levodopa. Certain anxiety is normal, such as during family crises and arguments. If a person has been nervous all of their life, levodopa will not be the solution; such anxiety is not due to brain dopamine deficiency. However, anxiety that develops after, or a little before the onset of DLB, PDD, or Parkinson’s disease is different. If recently, small issues have provoked panic and this is not a lifelong pattern, levodopa therapy may prove helpful. The anxiety experienced by those with DLB or PDD may occasionally reach crisis proportions. Emergency room physicians are familiar with older adults being brought in by concerned family members because “mom is in a panic.” Sometimes a Valium-like drug is prescribed to establish a quick response. Medications from the Valium class are termed benzodiazepines and include such agents as alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), as well as Valium itself (diazepam). Benzodiazepines are very sedating, which is beneficial in the emergency room to relax the nervous person; however, ongoing sedation is not acceptable on a long-term basis. Moreover, these drugs contribute to imbalance (fall risk) and tend to impair thinking.


1991 ◽  
Vol 19 (1) ◽  
pp. 131-136 ◽  
Author(s):  
Keith Hawton

The introduction of sex therapy two decades ago was accompanied by largely uncritical enthusiasm, with the result that too few careful evaluative studies were conducted. Those that were indicated that a weekly or twice weekly schedule of treatment sessions was best and that treatment by individual therapists was as effective as co-therapy. Some of the major prognostic factors and the long-term results of sex therapy have now been elucidated. Low sexual desire has emerged as a problem for which our now traditional methods of treatment are often inadequate and new therapeutic approaches are required. Current efforts to explore the beliefs and cognitive processes associated with erectile dysfunction are proving rewarding and are likely to enrich therapeutic interventions in the future. Attention should now be paid to the beliefs and cognitions associated with other sexual dysfunctions, both male and female.


2016 ◽  
Vol 263 (5) ◽  
pp. 895-905 ◽  
Author(s):  
Elena Lezcano ◽  
Juan Carlos Gómez-Esteban ◽  
Beatriz Tijero ◽  
Gaizka Bilbao ◽  
Imanol Lambarri ◽  
...  

1997 ◽  
Vol 99 ◽  
pp. S160
Author(s):  
V. Tjumikov ◽  
A. Kadykov ◽  
V. Peresedov ◽  
A. Shirshov ◽  
E. Sungurov ◽  
...  

2010 ◽  
Vol 25 (5) ◽  
pp. 578-586 ◽  
Author(s):  
Elena Moro ◽  
Andres M. Lozano ◽  
Pierre Pollak ◽  
Yves Agid ◽  
Stig Rehncrona ◽  
...  

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Stephanie Cernera ◽  
Robert S. Eisinger ◽  
Joshua K. Wong ◽  
Kwo Wei David Ho ◽  
Janine Lobo Lopes ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document